<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02064894</url>
  </required_header>
  <id_info>
    <org_study_id>OUCH</org_study_id>
    <secondary_id>MOP-125943</secondary_id>
    <nct_id>NCT02064894</nct_id>
  </id_info>
  <brief_title>Oral Analgesic Utilization for CHildhood Musculoskeletal Injuries</brief_title>
  <official_title>A Randomized Controlled Trial of Oral Analgesic Utilization for Pain Management of CHildhood Musculoskeletal Injuries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Justine's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Justine's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pain management for children presenting to the emergency department (ED) with an injured limb&#xD;
      is often under-treated, even though it is known that broken arms and legs cause moderate to&#xD;
      severe pain. Further, children are less likely to receive appropriate pain medicine than&#xD;
      adults with similar injuries. This study aims to improve the pain treatment of children who&#xD;
      present to the ED with a suspected fracture, or broken bone or severe sprain. The&#xD;
      investigators will compare the use of 3 different possible medication combinations (ibuprofen&#xD;
      alone, oral morphine alone, or combined ibuprofen and oral morphine) to determine which&#xD;
      combination is the best at treating children's pain. The investigators also plan to verify&#xD;
      the safety of using these different drugs to treat children's pain.&#xD;
&#xD;
      The investigators strongly believe that children's pain should be optimally treated in the&#xD;
      ED. Adequately relieving children's pain is crucial, as inadequate pain treatment can have&#xD;
      both short and longterm effects on the child. It also generates unnecessary stress for both&#xD;
      the child and their caregivers/parents. Given this knowledge, the investigators feel that&#xD;
      their study has the potential to impact care provided in EDs, and improve pain management&#xD;
      safely, for children.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale. Musculoskeletal trauma (MSK-T) in children is very common and almost universally&#xD;
      painful. Standards for children's pain management of MSK-T in the Emergency Department (ED)&#xD;
      vary greatly between Canadian hospitals and, overall, pain is very poorly treated. This&#xD;
      inadequate pain treatment can have significant acute and chronic negative effects. Previous&#xD;
      studies have determined that monotherapy with ibuprofen, the most commonly prescribed oral&#xD;
      analgesic in the ED, is likely providing inadequate pain management for children. In response&#xD;
      to this problem, clinicians have turned back to classic oral opioids (eg morphine) and are&#xD;
      experimenting with combination therapies. To date, few studies have focused on the efficacy&#xD;
      of a combination of a non-steroidal anti-inflammatory drug (NSAID) (eg ibuprofen) and an&#xD;
      opioid (eg morphine). Such a combination of analgesics is known to potentiate pain relief by&#xD;
      blocking it at the level of both the peripheral and the central nervous system. By combining&#xD;
      two drugs with different mechanisms of action, we may be able to provide additive analgesic&#xD;
      effects. To our knowledge, no studies have ever studied the efficacy and safety of this&#xD;
      combination of medication for MSK-T in pediatric EDs. Primary Hypothesis: For children with a&#xD;
      MSK-T in the ED, the addition of morphine to ibuprofen is safe and provides better pain&#xD;
      relief than either of the two drugs alone. Primary Research Question: For children with a&#xD;
      MSK-T in the ED, is a combination of oral morphine (0.2 mg/kg) and oral ibuprofen (10 mg/kg)&#xD;
      more efficacious than either of the two drugs, alone, in decreasing pain scores to &lt;30 mm, 60&#xD;
      minutes after administration?&#xD;
&#xD;
      Methods. Design: This study is a double-blind, placebo-controlled, two center, three-arm,&#xD;
      randomized clinical trial (RCT). Patients will be randomized to receive either: (a) ibuprofen&#xD;
      (10mg/kg) + placebo or (b) morphine (0.2 mg/kg) + placebo or (c) morphine (0.2mg/kg) +&#xD;
      ibuprofen (10mg/kg). Setting: Stollery Children's Hospital (Edmonton, AB) and CHU&#xD;
      Ste.Justine's pediatric hospital (Montreal, PQ). Inclusion criteria: We will include&#xD;
      children: (a) between the ages of 8 and 17 years; (b) visiting the ED with an injured upper&#xD;
      or lower limb that is neither obviously deformed, nor neurovascularly compromised, (c) with a&#xD;
      self-reported pain score &gt;30 mm on a 0 to100mm Visual Analogue Scale (VAS), where 0 mm&#xD;
      corresponds to no pain and 100 mm to the worst pain the child has experienced, and (d) who&#xD;
      understand French or English. Sample Size: Based on previous studies, we expect that between&#xD;
      25-52% (Clark et al., 2007, Le May et al., 2013) of children will achieve a VAS &lt; 30 mm at 60&#xD;
      minutes in the ibuprofen arm. We have conservatively set the proportion of children with VAS&#xD;
      &lt; 30 mm at 60 min to 50%. A sample size of 500 will be then necessary to provide at least 80%&#xD;
      power to detect a 20% absolute difference in proportion using a two-tailed with an alpha&#xD;
      level of 5%. In order to ensure an overall alpha level of 5%, a Bonferroni correction has&#xD;
      been applied in order to take into account the 3 pairwise comparisons that will be performed.&#xD;
      Primary Outcome and Measurement: The primary outcome measure will be pain intensity score&#xD;
      under 30 mm at 60-minutes after medication administration, using the VAS). Primary Safety&#xD;
      Outcomes: We will also assess clinical measures of safety by monitoring oxygen saturation at&#xD;
      30 minutes intervals, up until 120 minutes. Level of sedation/alertness, as well as the&#xD;
      respiratory rate, of each child will be monitored at set time points in the study, up until&#xD;
      120 minutes. Participating children will be followed up (via phone call) at 24 hours, to&#xD;
      record any latent side effects or adverse events. Further, acceptability of the intervention&#xD;
      will be assessed.&#xD;
&#xD;
      Relevance: Our proposed work will be the first RCT to investigate if there is some additive&#xD;
      effect of a bi-therapy of pain with ibuprofen and morphine. In summary, currently available&#xD;
      research supports ibuprofen as the monotherapy agent of choice. However, given concerns&#xD;
      regarding its ability to provide adequate relief on its own, smaller studies looked at&#xD;
      morphine as a possible alternative combined to ibuprofen. Very few studies of analgesic&#xD;
      combinations exist, and as such, we have yet to identify the optimal ED pain management&#xD;
      strategy for children with MSK-T. A larger trial with careful control over principal sources&#xD;
      of bias and a rigorous approach to safety data collection will provide clinicians with strong&#xD;
      evidence regarding efficacy and safety on new therapeutic strategies for pain management&#xD;
      related to MSK-T in the pediatric EDs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 8, 2013</start_date>
  <completion_date type="Actual">June 22, 2015</completion_date>
  <primary_completion_date type="Actual">June 22, 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Intensity - Percentage of Children Who Achieved VAS &lt; 30 mm</measure>
    <time_frame>60 minutes post-analgesia</time_frame>
    <description>Percentage of participants which pain intensity has decreased under 30 mm on the VAS at 60 minutes.&#xD;
The Visual Analogue Scale is a 0 to 100 mm continuous scale measuring the pain intensity. Score of 0=&quot;No Pain&quot;; Score of 100=&quot;Worst imaginable pain&quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Event - Side Effects and Serious Adverse Events</measure>
    <time_frame>60, 90 and 120 minutes</time_frame>
    <description>To verify the occurence of any serious adverse event, such as respiratory depression or deep sedation, during all the time-periods of the study</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">501</enrollment>
  <condition>Musculoskeletal Injury</condition>
  <arm_group>
    <arm_group_label>oral morphine and oral ibuprofen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral morphine (syrup) 0.2mg/kg (max. 15 mg) and oral ibuprofen (syrup) 10mg/kg (max. 600 mg) both administered once during the 2 hour-study time frame</description>
  </arm_group>
  <arm_group>
    <arm_group_label>morphine and placebo of ibuprofen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral morphine 0.2mg/kg (max. 15 mg) and a placebo of ibuprofen both administered once during the 2-hour time frame of the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ibuprofen and placebo of morphine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ibuprofen 10mg/kg (max. 600 mg) and placebo of morphine both administered once during the 2-hour time frame of the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral morphine and oral ibuprofen</intervention_name>
    <description>The combination of oral morphine and oral ibuprofen is one of the Experimental arm group</description>
    <arm_group_label>oral morphine and oral ibuprofen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral morphine</intervention_name>
    <description>Oral morphine 0.2 mg/kg (syrup) up to a maximum dosage of 15 mg, administered once during the study</description>
    <arm_group_label>morphine and placebo of ibuprofen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral ibuprofen</intervention_name>
    <description>oral ibuprofen combine to a placebo is the active comparator</description>
    <arm_group_label>ibuprofen and placebo of morphine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Between the ages of 6 and 17 years&#xD;
&#xD;
          -  Presenting to the ED with a musculoskeletal (MSK) trauma to either of the upper or&#xD;
             lower limbs that is neither obviously deformed, nor neurovascularly compromised&#xD;
&#xD;
          -  Self-reported pain score &gt;29 mm on a 0 to 100mm Visual Analogue Scale (VAS)&#xD;
&#xD;
          -  Able to understand French or English.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known allergy to morphine, ibuprofen, or artificial colouring&#xD;
&#xD;
          -  MSK trauma that are suspected to be due to child abuse, as determined by the triage&#xD;
             nurse&#xD;
&#xD;
          -  Inability to self-report pain&#xD;
&#xD;
          -  Chronic pain issues that require daily analgesic use&#xD;
&#xD;
          -  NSAID or opioid analgesic use within three hours prior to presentation to triage&#xD;
             (Exception of acetaminophen)&#xD;
&#xD;
          -  Trauma to more than one limb (except fingers and toes)&#xD;
&#xD;
          -  Known hepatic or renal disease/dysfunction&#xD;
&#xD;
          -  Known bleeding disorder&#xD;
&#xD;
          -  Neuro-cognitive disability that precludes patients from assenting and participating to&#xD;
             the study.&#xD;
&#xD;
          -  Known history of snoring consistently for the past 5 nights&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sylvie Le May, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Justine's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stollery Children's Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children Hospital of Eastern Ontario</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St.Justine's Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 3C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>February 14, 2014</study_first_submitted>
  <study_first_submitted_qc>February 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2014</study_first_posted>
  <results_first_submitted>November 22, 2016</results_first_submitted>
  <results_first_submitted_qc>April 24, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 3, 2017</results_first_posted>
  <last_update_submitted>April 24, 2017</last_update_submitted>
  <last_update_submitted_qc>April 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. Justine's Hospital</investigator_affiliation>
    <investigator_full_name>Sylvie Le May</investigator_full_name>
    <investigator_title>Professor and Researcher</investigator_title>
  </responsible_party>
  <keyword>children</keyword>
  <keyword>analgesia</keyword>
  <keyword>musculoskeletal injury</keyword>
  <keyword>emergency</keyword>
  <keyword>opioids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
    <mesh_term>Morphine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Assessed for eligibility (n=5127) Excluded (n=4626)&#xD;
Not meeting inclusion criteria (n=1670)&#xD;
Excluded as per exclusion criteria (n=663)&#xD;
Declined to participate (n=874)&#xD;
Not evaluated (n=1144)&#xD;
Other reasons (n=275) Randomized (n=501)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Oral Morphine and Oral Ibuprofen</title>
          <description>Oral morphine (syrup) 0.2mg/kg (max. 15 mg) and oral ibuprofen (syrup) 10mg/kg (max. 600 mg) both administered once during the 2 hour-study time frame&#xD;
oral morphine and oral ibuprofen: The combination of oral morphine and oral ibuprofen is one of the Experimental arm group</description>
        </group>
        <group group_id="P2">
          <title>Morphine and Placebo of Ibuprofen</title>
          <description>Oral morphine 0.2mg/kg (max. 15 mg) and a placebo of ibuprofen both administered once during the 2-hour time frame of the study&#xD;
Oral morphine: Oral morphine 0.2 mg/kg (syrup) up to a maximum dosage of 15 mg, administered once during the study</description>
        </group>
        <group group_id="P3">
          <title>Ibuprofen and Placebo of Morphine</title>
          <description>Ibuprofen 10mg/kg (max. 600 mg) and placebo of morphine both administered once during the 2-hour time frame of the study&#xD;
Oral ibuprofen: oral ibuprofen combine to a placebo is the active comparator</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="99">Received allocated intervention (n=98)&#xD;
Did not receive intervention (n=1)</participants>
                <participants group_id="P2" count="201">Received allocated intervention (n=198)&#xD;
Did not receive allocated intervention (n=3)</participants>
                <participants group_id="P3" count="201">Received allocated intervention (n=199)&#xD;
Did not receive allocated intervention (n=2)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Available at T-60</title>
              <participants_list>
                <participants group_id="P1" count="91"/>
                <participants group_id="P2" count="188"/>
                <participants group_id="P3" count="177"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Avalaible at T-90</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
                <participants group_id="P2" count="134"/>
                <participants group_id="P3" count="129"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="99"/>
                <participants group_id="P3" count="86"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="102"/>
                <participants group_id="P3" count="115"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="102"/>
                <participants group_id="P3" count="115"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Oral Morphine and Oral Ibuprofen</title>
          <description>Oral morphine (syrup) 0.2mg/kg (max. 15 mg) and oral ibuprofen (syrup) 10mg/kg (max. 600 mg) both administered once during the 2 hour-study time frame&#xD;
oral morphine and oral ibuprofen: The combination of oral morphine and oral ibuprofen is one of the Experimental arm group</description>
        </group>
        <group group_id="B2">
          <title>Morphine and Placebo of Ibuprofen</title>
          <description>Oral morphine 0.2mg/kg (max. 15 mg) and a placebo of ibuprofen both administered once during the 2-hour time frame of the study&#xD;
Oral morphine: Oral morphine 0.2 mg/kg (syrup) up to a maximum dosage of 15 mg, administered once during the study</description>
        </group>
        <group group_id="B3">
          <title>Ibuprofen and Placebo of Morphine</title>
          <description>Ibuprofen 10mg/kg (max. 600 mg) and placebo of morphine both administered once during the 2-hour time frame of the study&#xD;
Oral ibuprofen: oral ibuprofen combine to a placebo is the active comparator</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="91"/>
            <count group_id="B2" value="188"/>
            <count group_id="B3" value="177"/>
            <count group_id="B4" value="456"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.2" spread="2.6"/>
                    <measurement group_id="B2" value="11.7" spread="2.7"/>
                    <measurement group_id="B3" value="12.0" spread="2.7"/>
                    <measurement group_id="B4" value="11.9" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>6-11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="85"/>
                    <measurement group_id="B3" value="74"/>
                    <measurement group_id="B4" value="198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12-17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="103"/>
                    <measurement group_id="B4" value="258"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="84"/>
                    <measurement group_id="B4" value="204"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="106"/>
                    <measurement group_id="B3" value="93"/>
                    <measurement group_id="B4" value="252"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>VAS score at Baseline - Continuous</title>
          <description>The Visual Analogue Scale is a 0 to 100 mm continuous scale measuring the pain intensity. Score of 0=&quot;No Pain&quot;; Score of 100=&quot;Worst imaginable pain&quot;</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.9" spread="15.5"/>
                    <measurement group_id="B2" value="60.8" spread="15.8"/>
                    <measurement group_id="B3" value="61.0" spread="17.1"/>
                    <measurement group_id="B4" value="60.9" spread="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>VAS score at Baseline stratified by pain intensity</title>
          <description>The Visual Analogue Scale is a 0 to 100 mm continuous scale measuring the pain intensity. Score of 0=&quot;No Pain&quot;; Score of 100=&quot;Worst imaginable pain&quot;</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>30-69 mm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="128"/>
                    <measurement group_id="B3" value="121"/>
                    <measurement group_id="B4" value="313"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; 69 mm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="56"/>
                    <measurement group_id="B4" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Injury type - n(%)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Fracture</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="65"/>
                    <measurement group_id="B4" value="175"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Soft tissue injury</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="117"/>
                    <measurement group_id="B3" value="112"/>
                    <measurement group_id="B4" value="277"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Injury location - n(%)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Wrist</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="77"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Ankle</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="96"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Knee</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="67"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Foot</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Elbow</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Forearm</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="54"/>
                    <measurement group_id="B4" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain Intensity - Percentage of Children Who Achieved VAS &lt; 30 mm</title>
        <description>Percentage of participants which pain intensity has decreased under 30 mm on the VAS at 60 minutes.&#xD;
The Visual Analogue Scale is a 0 to 100 mm continuous scale measuring the pain intensity. Score of 0=&quot;No Pain&quot;; Score of 100=&quot;Worst imaginable pain&quot;</description>
        <time_frame>60 minutes post-analgesia</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Morphine and Oral Ibuprofen</title>
            <description>Oral morphine (syrup) 0.2mg/kg (max. 15 mg) and oral ibuprofen (syrup) 10mg/kg (max. 600 mg) both administered once during the 2 hour-study time frame&#xD;
oral morphine and oral ibuprofen: The combination of oral morphine and oral ibuprofen is one of the Experimental arm group</description>
          </group>
          <group group_id="O2">
            <title>Morphine and Placebo of Ibuprofen</title>
            <description>Oral morphine 0.2mg/kg (max. 15 mg) and a placebo of ibuprofen both administered once during the 2-hour time frame of the study&#xD;
Oral morphine: Oral morphine 0.2 mg/kg (syrup) up to a maximum dosage of 15 mg, administered once during the study</description>
          </group>
          <group group_id="O3">
            <title>Ibuprofen and Placebo of Morphine</title>
            <description>Ibuprofen 10mg/kg (max. 600 mg) and placebo of morphine both administered once during the 2-hour time frame of the study&#xD;
Oral ibuprofen: oral ibuprofen combine to a placebo is the active comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Intensity - Percentage of Children Who Achieved VAS &lt; 30 mm</title>
          <description>Percentage of participants which pain intensity has decreased under 30 mm on the VAS at 60 minutes.&#xD;
The Visual Analogue Scale is a 0 to 100 mm continuous scale measuring the pain intensity. Score of 0=&quot;No Pain&quot;; Score of 100=&quot;Worst imaginable pain&quot;</description>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="188"/>
                <count group_id="O3" value="177"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.0" lower_limit="24.2" upper_limit="43.1"/>
                    <measurement group_id="O2" value="29.3" lower_limit="23.2" upper_limit="36.1"/>
                    <measurement group_id="O3" value="29.9" lower_limit="23.7" upper_limit="37.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.81</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serious Adverse Event - Side Effects and Serious Adverse Events</title>
        <description>To verify the occurence of any serious adverse event, such as respiratory depression or deep sedation, during all the time-periods of the study</description>
        <time_frame>60, 90 and 120 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Morphine and Oral Ibuprofen</title>
            <description>Oral morphine (syrup) 0.2mg/kg (max. 15 mg) and oral ibuprofen (syrup) 10mg/kg (max. 600 mg) both administered once during the 2 hour-study time frame&#xD;
oral morphine and oral ibuprofen: The combination of oral morphine and oral ibuprofen is one of the Experimental arm group</description>
          </group>
          <group group_id="O2">
            <title>Morphine and Placebo of Ibuprofen</title>
            <description>Oral morphine 0.2mg/kg (max. 15 mg) and a placebo of ibuprofen both administered once during the 2-hour time frame of the study&#xD;
Oral morphine: Oral morphine 0.2 mg/kg (syrup) up to a maximum dosage of 15 mg, administered once during the study</description>
          </group>
          <group group_id="O3">
            <title>Ibuprofen and Placebo of Morphine</title>
            <description>Ibuprofen 10mg/kg (max. 600 mg) and placebo of morphine both administered once during the 2-hour time frame of the study&#xD;
Oral ibuprofen: oral ibuprofen combine to a placebo is the active comparator</description>
          </group>
        </group_list>
        <measure>
          <title>Serious Adverse Event - Side Effects and Serious Adverse Events</title>
          <description>To verify the occurence of any serious adverse event, such as respiratory depression or deep sedation, during all the time-periods of the study</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="188"/>
                <count group_id="O3" value="177"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Side effects</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Oral Morphine and Oral Ibuprofen</title>
          <description>Oral morphine (syrup) 0.2mg/kg (max. 15 mg) and oral ibuprofen (syrup) 10mg/kg (max. 600 mg) both administered once during the 2 hour-study time frame&#xD;
oral morphine and oral ibuprofen: The combination of oral morphine and oral ibuprofen is one of the Experimental arm group</description>
        </group>
        <group group_id="E2">
          <title>Morphine and Placebo of Ibuprofen</title>
          <description>Oral morphine 0.2mg/kg (max. 15 mg) and a placebo of ibuprofen both administered once during the 2-hour time frame of the study&#xD;
Oral morphine: Oral morphine 0.2 mg/kg (syrup) up to a maximum dosage of 15 mg, administered once during the study</description>
        </group>
        <group group_id="E3">
          <title>Ibuprofen and Placebo of Morphine</title>
          <description>Ibuprofen 10mg/kg (max. 600 mg) and placebo of morphine both administered once during the 2-hour time frame of the study&#xD;
Oral ibuprofen: oral ibuprofen combine to a placebo is the active comparator</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Others</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="177"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="188"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="177"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>High attrition rate between the time of randomization and the 120 minutes following analgesic administration; The dose of oral morphine was within the recommended range, but higher doses have been used in other trials for MSK pain relief in children.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Sylvie Le May</name_or_title>
      <organization>CHU Ste-Justine Hospital</organization>
      <phone>514-343-6384</phone>
      <email>sylvie.lemay@umontreal.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

